Bladder Cancer Coverage from Every Angle
Advertisement
Advertisement

Thomas Flaig, MD, on NCCN Clinical Practice Guidelines in Oncology®: Their Increasing Importance in Bladder Cancer

Posted: Friday, October 30, 2020

With a number of newly approved drugs for bladder cancer after decades of little progress, Thomas Flaig, MD, of the University of Colorado Denver, talks about why guidelines are so vital to helping clinicians understand how these therapies fit into the existing treatment paradigm.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.